Similar articles

• Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.

  Idris I, Warren G, Donnelly R. Idris I, et al. Arch Intern Med. 2012 Jul 9;172(13):1005-11. doi: 10.1001/archinternmed.2012.1938. Arch Intern Med. 2012. PMID: 22688528
• Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus.

  Colucciello M. Colucciello M. Arch Ophthalmol. 2005 Sep;123(9):1273-5. doi: 10.1001/archopht.123.9.1273. Arch Ophthalmol. 2005. PMID: 16157815 No abstract available.
• Macular edema and thiazolidinediones.

  Colucciello M, Ryan E. Colucciello M, et al. Arch Ophthalmol. 2010 Dec;128(12):1630-1; author reply 1631-2. doi: 10.1001/archophthalmol.2010.287. Arch Ophthalmol. 2010. PMID: 21149797 No abstract available.
• How safe is the use of thiazolidinediones in clinical practice?

  Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Rizos CV, et al. Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821. Expert Opin Drug Saf. 2009. PMID: 19236215 Review.
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association. Nesto RW, et al. Circulation. 2003 Dec 9;108(23):2941-8. doi: 10.1161/01.CIR.0000103683.99399.7E. Circulation. 2003. PMID: 14662691 Review. No abstract available.